FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4205383779> ?p ?o ?g. }

• W4205383779 endingPage "185" @default.
• W4205383779 startingPage "185" @default.
• W4205383779 abstract "Background: A favourable dose distribution has been described for proton beam therapy (PBT) of anal cancer in dosimetric studies. The relationship between dosimetric parameters in bone marrow and haematologic toxicity, treatment interruptions, and treatment efficacy has also been documented. There are only few references on clinical results of PBT for anal cancer. The primary objective of the retrospective study was to assess the efficacy of pencil beam scanning intensity-modulated proton therapy (PBS IMPT) in the definitive chemoradiotherapy of anal cancer. Secondary objectives were established to identify the risks of acute chronic toxicity risks and to assess colostomy rates. Materials and methods: Patients were treated for biopsy-proven squamous cell cancer (SCC) of the anus at initial or advanced stages. Eligible patients received PBS IMPT at a single institution. Treatment was administered in two volumes: 1-tumour with margins plus involved lymph nodes; 2-regional lymph node groups: perirectal (mesorectal), obturatory, inguinal, internal, external, and common iliac. The total doses of 57.5 GyE and 45 GyE, respectively, were administered in volumes 1 and 2 in 25 fractions, 5 fractions per week, respectively (a simultaneous integrated boost). Concomitant chemotherapy cisplatinum (CDDP) plus 5-FU or CDDP plus capecitabine was administered as per protocol. The treatment effect was assessed using DRE (digital rectal examination) and MRI (magnetic resonance imaging) within the follow-up period. Toxicity was scaled using CTCAE version 4.0 criteria. Results: 39 of 41 patients treated during the period of February 2014-August 2021 were eligible for analysis. All patients completed treatment, 76.9% without interruption. The median treatment time was 35 days (32-35). The median follow-up period was 30 months, 34 patients are alive to-date, 5 patients died prior to the date of analysis, and 2 deaths were unrelated to the primary disease. The 2-year overall survival, relapse-free survival, and colostomy-free survival were 94.2%, 93.8%, and 91.0%, respectively. Complete regression was achieved in 36 patients (92.3%), partial regression was achieved in 2 (5.1%), and immediate progression at end of treatment occurred in 1 patient (2.6%). Salvage resection was indicated for two patients in partial regression and due to severe chronic dermatologic toxicity. The grade 3 and 4 haematological toxicity rates were 7.7% and 5.1%, respectively. The most frequent non-haematological acute toxicities of grade 3-4 observed were dermatitis (23.1%), diarrhoea (7.7%), and dehydration (7.7%). Chronic toxicity emerged predominantly as skin atrophy/ulceration grade 2 (26.5%) and grade 3-4 (5.8%), and radiation proctitis grade 2 (38.2%) and grade 3 (2.9%). Discussion, conclusions: This single-institution study showed the high efficacy of PBS IMPT, achieving a high rate of complete regression. The haematological acute toxicity of grade 3-4 remained low; however, the impact of altered chemotherapy (CDDP instead of mitomycin C) remains unclear. The incidence of other acute toxicities shares similarity with photon therapy investigated in large studies. The acute toxicity completely resolved in all patients, had no lethal outcomes, and never resulted in the necessity for colostomy. By contrast, it was chronic toxicity, skin ulceration, perirectal fistulation, and fibrosis that resulted in salvage surgery and/or the need for a colostomy. A challenging question remains: to what extent can PBT prevent chronic toxicity? Longer follow-up remains necessary." @default.
• W4205383779 created "2022-01-25" @default.
• W4205383779 creator A5008593941 @default.
• W4205383779 creator A5013685945 @default.
• W4205383779 creator A5016798070 @default.
• W4205383779 creator A5035297585 @default.
• W4205383779 creator A5039972907 @default.
• W4205383779 creator A5041030036 @default.
• W4205383779 creator A5045078090 @default.
• W4205383779 creator A5046024187 @default.
• W4205383779 creator A5054321193 @default.
• W4205383779 creator A5069803121 @default.
• W4205383779 creator A5082798227 @default.
• W4205383779 date "2021-12-31" @default.
• W4205383779 modified "2023-10-16" @default.
• W4205383779 title "Pencil Beam Scanning (PBS) Intensity-Modulated Proton Therapy (IMPT) Chemoradiotherapy for Anal Canal Cancer—Single Institution Experience" @default.
• W4205383779 cites W1815414313 @default.
• W4205383779 cites W1819865887 @default.
• W4205383779 cites W2003345164 @default.
• W4205383779 cites W2004367809 @default.
• W4205383779 cites W2047348005 @default.
• W4205383779 cites W2054358001 @default.
• W4205383779 cites W2055442814 @default.
• W4205383779 cites W2076341925 @default.
• W4205383779 cites W2092767351 @default.
• W4205383779 cites W2126228166 @default.
• W4205383779 cites W2158244375 @default.
• W4205383779 cites W2164644812 @default.
• W4205383779 cites W2176502570 @default.
• W4205383779 cites W2527956456 @default.
• W4205383779 cites W2790616350 @default.
• W4205383779 cites W2808916511 @default.
• W4205383779 cites W2811321492 @default.
• W4205383779 cites W2946398268 @default.
• W4205383779 cites W2954664636 @default.
• W4205383779 cites W776995397 @default.
• W4205383779 doi "https://doi.org/10.3390/cancers14010185" @default.
• W4205383779 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35008349" @default.
• W4205383779 hasPublicationYear "2021" @default.
• W4205383779 type Work @default.
• W4205383779 citedByCount "1" @default.
• W4205383779 countsByYear W42053837792022 @default.
• W4205383779 crossrefType "journal-article" @default.
• W4205383779 hasAuthorship W4205383779A5008593941 @default.
• W4205383779 hasAuthorship W4205383779A5013685945 @default.
• W4205383779 hasAuthorship W4205383779A5016798070 @default.
• W4205383779 hasAuthorship W4205383779A5035297585 @default.
• W4205383779 hasAuthorship W4205383779A5039972907 @default.
• W4205383779 hasAuthorship W4205383779A5041030036 @default.
• W4205383779 hasAuthorship W4205383779A5045078090 @default.
• W4205383779 hasAuthorship W4205383779A5046024187 @default.
• W4205383779 hasAuthorship W4205383779A5054321193 @default.
• W4205383779 hasAuthorship W4205383779A5069803121 @default.
• W4205383779 hasAuthorship W4205383779A5082798227 @default.
• W4205383779 hasBestOaLocation W42053837791 @default.
• W4205383779 hasConcept C121608353 @default.
• W4205383779 hasConcept C126322002 @default.
• W4205383779 hasConcept C126838900 @default.
• W4205383779 hasConcept C141071460 @default.
• W4205383779 hasConcept C2775881188 @default.
• W4205383779 hasConcept C2778424827 @default.
• W4205383779 hasConcept C2779244869 @default.
• W4205383779 hasConcept C2779840525 @default.
• W4205383779 hasConcept C2780035688 @default.
• W4205383779 hasConcept C2780849966 @default.
• W4205383779 hasConcept C2781074409 @default.
• W4205383779 hasConcept C2989005 @default.
• W4205383779 hasConcept C509974204 @default.
• W4205383779 hasConcept C71924100 @default.
• W4205383779 hasConceptScore W4205383779C121608353 @default.
• W4205383779 hasConceptScore W4205383779C126322002 @default.
• W4205383779 hasConceptScore W4205383779C126838900 @default.
• W4205383779 hasConceptScore W4205383779C141071460 @default.
• W4205383779 hasConceptScore W4205383779C2775881188 @default.
• W4205383779 hasConceptScore W4205383779C2778424827 @default.
• W4205383779 hasConceptScore W4205383779C2779244869 @default.
• W4205383779 hasConceptScore W4205383779C2779840525 @default.
• W4205383779 hasConceptScore W4205383779C2780035688 @default.
• W4205383779 hasConceptScore W4205383779C2780849966 @default.
• W4205383779 hasConceptScore W4205383779C2781074409 @default.
• W4205383779 hasConceptScore W4205383779C2989005 @default.
• W4205383779 hasConceptScore W4205383779C509974204 @default.
• W4205383779 hasConceptScore W4205383779C71924100 @default.
• W4205383779 hasIssue "1" @default.
• W4205383779 hasLocation W42053837791 @default.
• W4205383779 hasLocation W42053837792 @default.
• W4205383779 hasLocation W42053837793 @default.
• W4205383779 hasLocation W42053837794 @default.
• W4205383779 hasOpenAccess W4205383779 @default.
• W4205383779 hasPrimaryLocation W42053837791 @default.
• W4205383779 hasRelatedWork W1569975733 @default.
• W4205383779 hasRelatedWork W1996610813 @default.
• W4205383779 hasRelatedWork W2022753627 @default.
• W4205383779 hasRelatedWork W2076481039 @default.
• W4205383779 hasRelatedWork W2896302822 @default.
• W4205383779 hasRelatedWork W2929105465 @default.
• W4205383779 hasRelatedWork W2932822888 @default.
• W4205383779 hasRelatedWork W2943245079 @default.

• next